Sermorelin dosage: what the studies used
Reviewed 16 sourcesPublished by PepVault
Sermorelin dosage in studies: 1 mcg/kg IV for testing, 30 mcg/kg nightly in children, 0.5 to 2 mg in older men. How it works and what users report.

- Last reviewed
- Sources
- 16
- Questions
- 8
- Compounds
- 3
The short answer
Studies dosed sermorelin by purpose. As a one-time test of the pituitary, it was given at 1 mcg/kg by IV. In a 110-child growth trial, the dose was 30 mcg/kg under the skin once daily at bedtime, for up to a year. Studies in older men used 0.5 to 2 mg, twice daily or nightly, for 2 to 6 weeks. These are research figures, not a dose for anyone.
Evidence: Human studies, mostly from the 1990s: one large open-label trial in children with growth hormone deficiency, small, short studies in older adults (19 people at most) and one 2017 chart review.

What is sermorelin?
Sermorelin is a shortened copy of the body's own signal for growth hormone. That signal, growth hormone-releasing hormone (GHRH), is a chain of 44 amino acids that the hypothalamus releases to tell the pituitary to make growth hormone16. Sermorelin keeps only the first 29 links of the chain, and those 29 are the shortest synthetic stretch that carries the full activity of the whole hormone1.
Unlike most peptides people track, it had a real career as an FDA-approved drug, sold as Geref. The FDA approved a 0.05 mg ampule on December 28, 1990, for testing whether the pituitary can release growth hormone, and 0.5 mg and 1 mg vials on September 26, 1997, to treat children with idiopathic growth hormone deficiency and growth failure91011.
The maker, EMD Serono, told the FDA in 2008 that it was discontinuing both products, and the approvals were withdrawn effective June 18, 2009. In 2013 the FDA reviewed its records, the literature and the post-marketing adverse event data, and determined that Geref was not withdrawn from sale for reasons of safety or effectiveness9.
Peptide SkySee Sermorelin as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
How does sermorelin work?
It does the hypothalamus's job. Sermorelin binds the GHRH receptor on the growth hormone-making cells of the anterior pituitary, and those cells release their own growth hormone, which in turn raises IGF-1112. Because it acts one step upstream, the body's brakes still apply: somatostatin and the feedback from IGF-1 keep shaping how much is released12. That is the main difference from injecting growth hormone itself. In the words of one trial team, describing earlier studies in children and young adults, GHRH raises GH and IGF-1 "while preserving physiological GH release"3.
The molecule is gone from the blood within minutes, and its effect lasts hours. In 10 healthy men given GHRH(1-29) by IV infusion, its disappearance half-time was about 4 minutes7. Yet after a single IV dose, growth hormone stayed raised for about 3 hours6, and in a nightly trial of a close variant, the release began within 10 minutes and lasted about 2 hours5.
That short life is why the studies dose it once or more a day, and why its relatives were built. CJC-1295, in its version with DAC, is a long-acting GHRH analog with an estimated half-life of 5.8 to 8.1 days, and the report of its trials in healthy adults opens by noting that GHRH's therapeutic use "is limited by its short duration of action"14. Tesamorelin, another GHRH analog, is FDA-approved, as Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy15.
What doses were used in sermorelin studies?
The dose tracked the job. A test needed one small IV dose; treatment needed a daily injection under the skin, at about 30 times the weight-based amount. Here is each study, who was in it and what it used.
| Study | Who | Dose and route | How often, how long |
|---|---|---|---|
| Diagnostic test1 | Children being tested for growth hormone deficiency | 1 mcg/kg by IV | Once |
| Dose-finding, 19936 | 30 healthy men aged 19 to 43 | From 0.25 mcg/kg by IV; the largest GH release came at 1 to 2 mcg/kg | Single doses |
| Children's growth trial, 19962 | 110 children with GH deficiency, before puberty and not treated before | 30 mcg/kg under the skin | Once daily at bedtime, up to 1 year |
| Older men, 19923 | 10 healthy men, average age 68 | 0.5 mg and 1 mg under the skin | Twice daily, 14 days at each dose |
| Older men, 19974 | 11 healthy men aged 64 to 76 | 2 mg under the skin | Nightly, 6 weeks |
| Older adults, 19975 | 10 women and 9 men aged 55 to 71, given a close variant | 10 mcg/kg under the skin | Nightly at 9 pm, 16 weeks |
| Clinic chart review, 201713 | 14 men on testosterone, average age 33 | 100 mcg of sermorelin, GHRP-2 and GHRP-6, as prescribed | Three times daily, about 134 days on average |
The doses in the table are what each study used. They describe the research, not a protocol to copy. The 1997 trial of older adults used [Nle27]GHRH(1-29), which differs from sermorelin at one of its 29 positions516.
Why so much more under the skin than by IV? One clue is breakdown on the way in. In anaesthetized rats, the total amount of the peptide reaching the circulation after an injection under the skin was estimated at only 4% of that after an IV injection, and the authors pointed to breakdown at the injection site or on the way into the blood8. That measurement is in rats; the human figure may differ.
What did the studies find?
In children, the 1996 trial is the largest. Average growth speed rose from 4.1 cm a year before treatment to 8.0 cm a year at 6 months and 7.2 cm a year at 12 months, and 74% of the children had a good response at 6 months. Bone age did not run ahead of height, and IGF-1 did not overshoot2. Data from a few children suggest the effect held for 36 months of continued treatment. As of the 1999 review, the once-daily schedule had not been compared head to head with growth hormone; when the same daily amount of sermorelin was given as an infusion or in three doses, growth speed rose less than with once-daily growth hormone injections1.
In older men, the 1992 study found that the 1 mg twice-daily dose raised 24-hour growth hormone and IGF-1 until they no longer differed significantly from the young men in the study; the significant rises came only at that higher dose. Fasting glucose, blood pressure and routine blood tests did not change3. The 1997 study of a single nightly 2 mg dose raised nighttime growth hormone but not IGF-1, improved two of six strength measures and an endurance test, and left body composition unchanged. Its authors concluded that single nightly doses are less effective than several doses a day4.
In older men and women, 16 weeks of the nightly variant raised IGF-1 within 2 weeks, and it stayed raised for 12 weeks before drifting back toward baseline by week 16. Skin got thicker in both sexes; lean mass, insulin sensitivity, well-being and libido improved in the men only5.
What dose do people use outside studies?
Community protocols use a fixed amount rather than a weight-based one. A 2026 review in Frontiers in Endocrinology recorded the pattern from a bodybuilding forum as 200 to 300 mcg under the skin once daily, typically before bedtime on an empty stomach, and labelled it self-reported online dosing, not a clinical recommendation12. None of the studies above tested that schedule in healthy adults. The same review concludes that clinically meaningful benefits in healthy people remain uncertain, because the human evidence is limited and largely indirect12.
For a schedule and how a dose reads on a syringe, PepVault's Dose Guide has a page at pepvault.app/lab/dosage/sermorelin; the library page, pepvault.app/peptides/sermorelin, covers its timeline and stacks.
What side effects did the studies report?
Across the trials it was well tolerated. The most common effects were a brief facial flush and some soreness where the injection went in1. The children's trial found no adverse changes in blood chemistry or hormones and no change in fasting glucose2. The 6-week trial in older men saw no significant adverse effects4. In the 16-week trial, the only one recorded was a rise in blood lipids that settled by the end of the study5.
What do people who use sermorelin report?
Commonly reported: deeper sleep and vivid dreams within the first one to two weeks, a short warm flush after the injection, mild redness at the site, and slow changes in recovery and skin that build over months rather than days.
These are user reports, not trial results. Of the trials above, the one that asked about sleep, the 16-week trial of the close variant, found no change in sleep quality, while skin thickness did rise5. Since the effects build slowly, the first weeks are a good time to note sleep, recovery and how the skin looks, as a baseline to compare against later.
Is sermorelin approved today?
Not as a marketed drug. FDA's approvals database lists the two Geref applications, both discontinued, and the FDA's 2013 determination means it may approve generic versions that refer to Geref if all other requirements are met91011. Outside that route, the 2026 review notes that real-world use is complicated by uncertain quality and composition in unregulated peptide supply chains12.
Sources
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173
- Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996. PubMed 8772599
- Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992. PubMed 1379256
- Vittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. PubMed 9005976
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536
- Wilton P et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993. PubMed 8329825
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. PubMed 7962295
- Rafferty B et al. Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J Endocrinol. 1985. PubMed 2866222
- U.S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection, 0.5 milligrams base/vial and 1.0 milligrams base/vial, and GEREF (sermorelin acetate) injection, 0.05 milligrams base/amp, were not withdrawn from sale for reasons of safety or effectiveness. Federal Register 78 FR 14095, March 4, 2013. federalregister.gov
- U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate) 0.05 mg/ampule, NDA 019863. accessdata.fda.gov
- U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate) 0.5 mg and 1 mg/vial, NDA 020443. accessdata.fda.gov
- Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. PubMed 42395176
- Sigalos JT et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PubMed 28830317
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- EGRIFTA SV (tesamorelin) prescribing information. Theratechnologies. DailyMed. dailymed.nlm.nih.gov
- UniProt P01286. Somatoliberin (growth hormone-releasing hormone), Homo sapiens. uniprot.org
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.